1. The influence of treatment on hormone receptor subgroups and breast cancer-specific mortality within US integrated healthcare systems
- Author
-
Cody Ramin, Gretchen L. Gierach, Mustapha Abubakar, Lene H. S. Veiga, Jacqueline B. Vo, Rochelle E. Curtis, Erin J. Aiello Bowles, Heather Spencer Feigelson, Diana S. M. Buist, Amy Berrington de Gonzalez, and Clara Bodelon
- Subjects
Cancer Research ,Oncology ,Receptors, Estrogen ,Delivery of Health Care, Integrated ,Receptor, ErbB-2 ,Humans ,Breast Neoplasms ,Female ,Prognosis ,Receptors, Progesterone ,Hormones ,Article ,Retrospective Studies - Abstract
Estrogen receptor (ER) + /progesterone receptor (PR) - or ER-/PR + breast cancer prognosis has not been well-described outside of clinical trials. We evaluated the relationship between ER/PR (ER + /PR-, ER-/PR + , ER + /PR + , ER-/PR-) subgroups and breast cancer-specific mortality within a general community setting in the US.A Retrospective cohort of 11,737 women diagnosed with breast cancer between 1990 and 2016 within US integrated healthcare systems (median follow-up = 7 years; 1,104 breast cancer-specific deaths) were included in this analysis. Cox proportional hazards models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) adjusting for site, demographic and clinicopathological characteristics, and treatment (surgery/radiotherapy, chemotherapy, endocrine therapy).Breast cancer-specific mortality was higher for those with ER + /PR- (n = 1,233) compared with ER + /PR + tumors (n = 8,439) before (HR = 1.43; 95% CI = 1.17-1.75) and after treatment adjustment (HR = 1.58; 95% CI = 1.27-1.97). ER + /PR- breast cancer-specific mortality remained higher than ER + /PR + tumors when stratified by treatment received. Breast cancer-specific mortality was similar in ER-/PR + (n = 161) compared with ER + /PR + tumors.Our findings suggest that ER + /PR- tumors may have worse breast cancer-specific mortality than ER + /PR + tumors in a community setting.
- Published
- 2021